NCT06607185 2026-04-22
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
Genmab
Actuate Therapeutics Inc.
Tyligand Pharmaceuticals (Suzhou) Limited
Genfleet Therapeutics (Shanghai) Inc.